Skip to main content

Depression Not Likely to Cause Cognitive Impairment


A new study suggests that depression often accompanies cognitive impairment but does not precede it.
"Traditionally, cognitive complaints and impairment in the presence of depression has been considered to be caused by the depression. Our study suggests that depression is not a cause of dementia but accompanies the onset of cognitive impairment," José Alejandro Luchsinger, MD, MPH, associate professor of medicine and epidemiology, Columbia University Medical Center, New York City, told Medscape Medical News.
The study was published online December 31, 2012 in Archives of Neurology.
Transition Time Crucial Period
Patients with mild cognitive impairment (MCI) and Alzheimer's disease (AD) often have depressive symptoms, but the mechanisms underlying the association remain unclear.
"Depression could be a risk factor for dementia, an early dementia symptom, a reaction to cognitive and functional disability, or a symptom of a related risk factor, such as cerebrovascular disease," Dr. Luchsinger and colleagues point out. "Vascular factors have been linked to late-life depression, and cerebrovascular disease might be an important contributor to MCI…. However, there is a paucity of data examining the association between depression and MCI."
Dr. José Alejandro Luchsinger
The researchers evaluated the association of late-life depression with MCI and dementia in a multiethnic group of 2160 community-dwelling Medicare recipients.
They report that depression at baseline was associated with prevalent MCI (odds ratio [OR], 1.4; 95% confidence interval [CI], 1.1 - 1.9) and prevalent dementia (OR, 2.2; 95% CI, 1.6 - 3.1).
Baseline depression was also associated with an increased risk for incident dementia (hazard ratio [HR], 1.7; 95% CI, 1.2 - 2.3) but not with incident MCI (HR, 0.9; 95% CI, 0.7 - 1.2).
In addition, individuals with MCI and coexisting depression at baseline had a higher risk for progression to dementia (HR, 2.0; 95% CI, 1.2 - 3.4), especially vascular dementia (HR, 4.3; 95% CI, 1.1 - 17.0), but not AD (HR, 1.9; 95% CI, 1.0 - 3.6).
"Our finding that depression was associated cross sectionally with both MCI and dementia and longitudinally only with dementia suggests that depression develops with the transition from normal cognition to dementia," the authors conclude.
Dr. Luchsinger said, "Clinicians should consider the possibility that depression and cognitive impairment could be the joint manifestation of a cognitive disorder, particularly in elderly persons. Our research did not directly address this, and more research is needed to understand if the depression is part of the cognitive process or a reaction to it."
Mechanisms?
"There has now been an accumulation of enough studies and enough data to say that people with a history of depression do have increased rates of cognitive decline and dementia in late life," Meryl Butters, PhD, neuropsychologist and associate professor of psychiatry, University of Pittsburgh School of Medicine, Pennsylvania, who was not involved in the study, noted in an interview with Medscape Medical News.
"The issue now really is, what are the mechanisms? What is it about a mood disorder earlier in life that might place you at risk for progressive dementia in late life? This study can't address that," she said.
Dr. Butters said "a handful" of researchers, including herself, are now looking at possible mechanisms behind depression and cognitive decline. "This is a very active area of investigation. It's likely that different mechanisms are at work in different people."
The authors have disclosed no relevant financial relationships.

Comments

Post a Comment

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such...
Post a Comment
Read more

Antidepressants Linked to Higher Diabetes Risk in Kids

Pediatric patients who use antidepressants may have an elevated risk for type 2 diabetes, the authors of a new study report. In a retrospective cohort study of more than 119,000 youths 5 to 20 years of age, the risk for incident type 2 diabetes was nearly twice as high among current users of certain types of antidepressants as among former users, Mehmet Burcu, PhD, and colleagues report in an article  published online October 16 in  JAMA Pediatrics . The risk intensified with increasing duration of use, greater cumulative doses, and higher daily doses of these antidepressants. The findings point to a growing need for closer monitoring of these products, including greater balancing of risks and benefits, in the pediatric population, the authors caution. They undertook the study because, despite growing evidence of an association between antidepressant use and an increased risk for type 2 diabetes in adults, similar research in pediatric patients was scarce. "To our know...
Post a Comment
Read more

FDA Decision Delayed for Truvada in HIV PrEP

June 11, 2012 — The US Food and Drug Administration (FDA) has delayed its decision on allowing the use of tenofovir disoproxil fumarate/emtricitabine ( Truvada , Gilead) as preexposure prophylaxis (PrEP) so that the proposed risk evaluation and mitigation strategy (REMS) can be reviewed. In early May, the FDA's Antiviral Drugs Advisory Committee  strongly backed  approval of the first-ever drug for the prevention of sexually acquired HIV-1 infection. However, concerns by the panel at the time included that people may neglect condom use if they feel they are protected by PrEP. Panelists were also concerned that uninfected people taking PrEP who become infected with HIV may not switch to a 3-drug regimen as recommended. According to the company, the FDA has postponed the target date to September 14 so it can review Gilead's REMS plan to help ensure that patients will not misuse the drug. The committee's recommendation for supplemental approval of tenofovir/emtricit...
Post a Comment
Read more